Sanaria’s Patents for Humanity Award Recognized in Virtual Ceremony hosted by the USPTO
Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults
Sanaria and its Bioko Island Malaria Elimination Project partners win the Concordia P3 Impact Award and Audience Choice Award
Sanaria Hosts Students from the National Student Leadership Conference
Sanaria exhibits at annual Rockville Science Day
On April 22nd Sanaria participated at the 29th annual Rockville Science Day. Our exhibit featured different stages of the mosquito life cycle and a liquid nitrogen demonstration. For many of the children it was their first time looking through a microscope. At Sanaria we strive to engage with our community and foster scientific curiosity. Check out the future scientists:|
Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon
Abstract
Controlled human malaria infection (CHMI) by direct venous inoculation (DVI) with 3,200 cryopreserved Plasmodium falciparum sporozoites (PfSPZ) consistently leads to parasitemia and malaria symptoms in malaria-naive adults. We used CHMI by DVI to investigate infection rates, parasite kinetics, and malaria symptoms in lifelong malaria-exposed (semi-immune) Gabonese adults with and without sickle cell trait. Eleven semi-immune Gabonese with normal hemoglobin (IA), nine with sickle cell trait (IS), and five nonimmune European controls with normal hemoglobin (NI) received 3,200 PfSPZ by DVI and were followed 28 days for parasitemia by thick blood smear (TBS) and quantitative polymerase chain reaction (qPCR) and |
New film, Hope for Bioko, showcases Sanaria’s work
Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial
Abstract
BACKGROUND:
Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive individuals. We aimed to assess the safety and protective efficacy of PfSPZ Vaccine against naturally acquired P falciparum in malaria-experienced adults in Mali.
METHODS:
After an open-label dose-escalation study in a pilot safety cohort, we did a double-blind, randomised, placebo-controlled trial based in Donéguébougou and surrounding villages in Mali. We recruited 18-35-year-old healthy adults who were randomly assigned (1:1) in a double-blind manner, with stratification by
Weill Cornell Alumni Association Honors Dr. Stephen Hoffman
Sanaria Earns ‘Bioscience Company Of The Year’ Award
Minister of Health and Social Welfare Discusses Malaria Vaccine Clinical Trial
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2011
The Quest for a Malaria Vaccine and the Man Who Risked Everything to Find It
Dr. Stephen Hoffman learned about malaria the hard way—by rolling up his sleeves and letting thousands of infected mosquitoes bite him.
Back in mid-1990s, Stephen Hoffman dipped his arm into a swarm of malaria-infected mosquitoes. But he didn’t expect to get sick. At the time, he thought he’d invented a vaccine that would keep him disease free.
He was wrong.